Has Jhanelle Gray, MD received payments from drug or device companies?

Yes. Drug and device makers reported $228,822 in general payments to Jhanelle Gray, MD across 155 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jhanelle Gray, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jhanelle Gray, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jhanelle Gray, MD

Internal Medicine · Tampa, FLNPI 1376599340

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $203,127 of the $228,822 with a category attached, or 88.8%. It is spread thinly across 27 manufacturers, the largest accounting for just 14.8%. Reporting peaked in 2023 at $70,619 and has fallen 55.2% since, to $31,659 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$228,822in general payments, 2019–2025

Across 155 payments — averaging $1476.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Gilead$34K
AstraZeneca$30K
Spectrum Pharmaceuticals Inc.$22K
EMD Serono, Inc.$21K
Merck$15K
Eli Lilly$14K
plus $93K from 21 others

$20,576,962in research payments, 2019–2025

Across 574 payments — averaging $35,848 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$16.9M
Pfizer$1.2M
AstraZeneca$1M
E.r. Squibb & Sons, L.L.C.$399K
Genentech, Inc.$269K
Janssen Research & Development, LLC$248K
plus $524K from 10 others

What the payments were for

Consulting fees$203,12789%
Speaking & faculty fees$15,1167%
Travel & lodging$6,8183%
Food & beverage$3,7292%
Education$320%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Gilead	10	$33,759
AstraZeneca	24	$30,365
Spectrum Pharmaceuticals Inc.	2	$22,024
EMD Serono, Inc.	15	$21,049
Merck	22	$15,072
Eli Lilly	5	$13,604
Novartis	7	$13,266
Regeneron	12	$11,328
Johnson & Johnson	5	$9,238
Pfizer	4	$8,740
Astrazeneca UK Limited	8	$5,825
Amgen	4	$5,555
Jazz Pharmaceuticals Inc.	2	$5,144
E.r. Squibb & Sons, L.L.C.	7	$5,121
Blueprint Medicines Corporation	3	$4,756
Janssen Scientific Affairs, LLC	4	$4,040
Coherus Oncology, Inc.	3	$4,016
Daiichi Sankyo Inc.	2	$2,900
Sanofi	1	$2,876
Takeda Pharmaceuticals U.S.A., Inc.	1	$2,625
AbbVie	3	$2,365
Genentech USA, Inc.	2	$1,984
Catalyst Pharmaceuticals, Inc.	2	$1,663
Merck Kgaa	2	$1,208
Astrazeneca AB	3	$158
Regeneron Healthcare Solutions, Inc.	1	$101
Novocure Inc.	1	$40

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LIBTAYO$11,158
RYBREVANT$9,238
TABRECTA$7,681
IMFINZI$7,102
TAGRISSO$6,550
LORBRENA$6,220
ZEPZELCA$5,144
BRAFTOVI$4,420
MEKTOVI$4,420
RETEVMO$4,400
LOQTORZI$3,750
VIZIMPRO$3,700
XALKORI$3,700
ALUNBRIG$2,625
IMDELLTRA (AMG 757)$2,058
KEYTRUDA$1,979
Trodelvy$1,890
FIRDAPSE$1,663
OPDIVO$1,500
EMD 1214063$321

How this compares

$228,822 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida →

Medicare billing

Part B allowed, 2024

$9,669

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Tampa

Andrew KuykendallTampa$322K
Anitha ReddyTampa$224K
Benjamin CreelanTampa$212K
Anne HermannTampa$139K
Mark LaflammeTampa$119K
Shahla BariTampa$56K
Haytham ElgammalMiami$2.2M
Keith RubinFort Lauderdale$2M
Michael SensionFort Lauderdale$1M
Quang NguyenOcala$434K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →